TargetBeta
NTRK1
neurotrophic receptor tyrosine kinase 1 · also TRK, TRKA, MTC · Immunoglobulin like domain containing
4 programs in company-led studies act on NTRK1, from 4 companies: 2 in phase 3, 2 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (4 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| regorafenibrule | Bayer | phase 4 | 404 running | ABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, MAPK11, PDGFRA, PDGFRB, RAF1, RET, TEK | ChEMBL |
| cenegerminrule | Dompé Farmaceutici S.p.A | phase 4 | 62 running | NTRK2, NTRK3 | ChEMBL |
| taletrectinibrule | Nuvation Bio | phase 3 | 115 running | NTRK2, NTRK3, ROS1 | ChEMBL |
| repotrectinibrule | Bristol-Myers Squibb | phase 3 | 93 running | ALK, CD74, NTRK2, NTRK3, PTK2, ROS1, SDC4, SRC | ChEMBL |
Also acted on by the same programs
Conditions their studies are in
- Carcinoma, Non-Small-Cell Lung, 2 programs
- Neoplasms, 2 programs
- Carcinoma, Hepatocellular, 1 program
- Colorectal Neoplasms, 1 program
- Conjunctivitis, Allergic, 1 program
- Corneal Diseases, 1 program
- Corneal Ulcer, 1 program
- Dry Eye Syndromes, 1 program
- Lymphoma, 1 program
- Lymphoma, Follicular, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Feb 2, 2027taletrectinib · Nuvation Bio · phase 3 · NCT07742384
- Feb 16, 2027repotrectinib · Bristol-Myers Squibb · phase 3 · NCT06140836
- Sep 2027cenegermin · Dompé Farmaceutici S.p.A · phase 4 · NCT07453888
- Sep 30, 2027regorafenib · Bayer · phase 4 · NCT02955940
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.